Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
6.67
+0.27 (4.22%)
At close: Aug 7, 2026, 4:00 PM EDT
6.70
+0.03 (0.45%)
After-hours: Aug 7, 2026, 7:34 PM EDT
Gyre Therapeutics Revenue
Gyre Therapeutics had revenue of $29.11M in the quarter ending June 30, 2026, a decrease of -2.12%. This brings the company's revenue in the last twelve months to $119.38M, up 13.53% year-over-year. In the year 2025, Gyre Therapeutics had annual revenue of $116.59M with 10.24% growth.
Revenue (ttm)
$119.38M
Revenue Growth
+13.53%
P/S Ratio
6.44
Revenue / Employee
$175,709
Employees
625
Market Cap
707.25M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 116.59M | 10.83M | 10.24% |
| Dec 31, 2024 | 105.76M | -7.69M | -6.78% |
| Dec 31, 2023 | 113.45M | 11.16M | 10.91% |
| Dec 31, 2022 | 102.29M | 94.95M | 1,293.98% |
| Dec 31, 2021 | 7.34M | -34.56M | -82.49% |
| Dec 31, 2020 | 41.90M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 6.00K | -1.01M | -99.41% |
| Dec 31, 2017 | 1.02M | 619.00K | 155.14% |
| Dec 31, 2016 | 399.00K | -1.35M | -77.20% |
| Dec 31, 2015 | 1.75M | -63.00K | -3.47% |
| Dec 31, 2014 | 1.81M | 1.29M | 246.65% |
| Dec 31, 2013 | 523.00K | -115.20M | -99.55% |
| Dec 31, 2012 | 115.72M | -79.55M | -40.74% |
| Dec 31, 2011 | 195.27M | 23.85M | 13.91% |
| Dec 31, 2010 | 171.43M | 121.30M | 242.00% |
| Dec 31, 2009 | 50.12M | 9.95M | 24.78% |
| Dec 31, 2008 | 40.17M | 17.02M | 73.51% |
| Dec 31, 2007 | 23.15M | -31.92M | -57.96% |
| Dec 31, 2006 | 55.07M | 52.71M | 2,233.81% |
| Dec 31, 2005 | 2.36M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Phathom Pharmaceuticals | 239.66M |
| Zevra Therapeutics | 136.07M |
| CytomX Therapeutics | 18.30M |
| Crescent Biopharma | 11.88M |
| Neurogene | 925.00K |
| Allogene Therapeutics | 22.00K |
GYRE News
- 2 days ago - Gyre Therapeutics Earnings release: Q2 2026 - Filings
- 2 days ago - Gyre Therapeutics Quarterly report: Q2 2026 - Filings
- 2 days ago - Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update - GlobeNewsWire
- 24 days ago - Gyre Therapeutics Appoints Three New Members to its Board of Directors - GlobeNewsWire
- 27 days ago - Gyre Therapeutics Registration statement: Registration filing - Filings
- 6 weeks ago - Gyre Therapeutics Registration statement: Registration filing - Filings
- 6 weeks ago - Gyre Therapeutics files to sell 30.22M shares of common stock for holders - TheFly
- 2 months ago - Gyre Therapeutics Transcript: AGM 2026 - Transcripts